rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Redhill Biopharma Ltd. - American Depositary Shares

RDHL · Nasdaq

Health CareBiotechnologyNot moving yet

RDHL stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 37.3% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$4,418
Officials’ trades on record
0
Institutions holding
14 (-1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1,517$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months3
Buyers · sellers0 · 1
WhoDidSharesTraded
Gilead RadayChief Operating Officersold14,310,000at $0.00011 Oct 2026filed 6 Oct 2026
Gilead RadayChief Operating Officersold14,130,000at $0.000110 Jul 2026filed 13 Jul 2026
Gilead RadayChief Operating Officersold15,740,000at $0.00016 Apr 2026filed 22 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders14-1 on the quarter
New · exited3 · 4
Reported value$270K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Yorkville Advisors Global, LPreduced · filed 6 Aug 2026122,131$107K-228,739−65.2%
GAGNON SECURITIES LLCunchanged · filed 5 Aug 202688,405$75K00.0%
CITADEL ADVISORS LLCadded · filed 14 Aug 202665,321$55K+44,648+216.0%
RHUMBLINE ADVISERSadded · filed 12 Aug 202613,755$12K+8,639+168.9%
Lido Advisors, LLCnew · filed 7 Aug 202611,009$9,303+11,009
GAMMA Investing LLCadded · filed 7 Jul 20266,957$5,879+273+4.1%
CITIGROUP INCnew · filed 3 Aug 20264,378$3,699+4,378
Federation des caisses Desjardins du Quebecunchanged · filed 14 Aug 20263,388$2,86300.0%
UBS Group AGreduced · filed 13 Aug 2026100$85-726−87.9%
MERCER GLOBAL ADVISORS INCnew · filed 11 Aug 202650$42+50
30 Sep 2024 – 30 Jun 2026
91316Sep 24Mar 25Sep 25Dec 25Jun 26

News

No headline names it lately.

Everyone who traded it

Gilead Raday Company insiderChief Operating Officer · last 1 Oct 20260 · 3

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 31 Dec 2025295%

Analyst forecasts

No analyst forecasts yet.